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Hypericin is a photodynamic compound activated by
either visible (400–700 nm) or UVA (320–400 nm) light,
and has been shown to inhibit the growth of a variety of
neoplastic cell types. In this study, hypericin was found
to inhibit proliferative responses of malignant T cells
derived from the blood of patients with cutaneous T cell
lymphoma. Control cells included peripheral blood
mononuclear cells (PBMC) from normal volunteers or
Epstein–Barr virus-transformed lymphocytes. Cells from
each of these populations were incubated with serial
dilutions of hypericin or 8-methoxypsoralen and then
stimulated with the mitogen ConA (10 mg per ml).
Cultures were prepared in the dark to minimize photoac-
tivation of the hypericin. Proliferation was measured by
[3H]thymidine labeling after 72 h. Hypericin, photoactiv-
ated with 1.1–3.3 J white light per cm2, inhibited cellular
proliferation of malignant T cells with IC50 values from
0.34 to 0.53 mM, normal PBMC with IC50 values of 0.11–
0.76 mM, and Epstein–Barr virus-transformed cells with
Hypericin is a naturally occurring photodynamic com-pound derived predominantly from the stems, petals,and leaves of the St. John’s Wort (Hypericum perforatum).It has been demonstrated to possess a number ofimportant biologic properties including potent anti-
viral activity (Meruelo et al, 1988; Lopez-Bazzocchi et al, 1991;
Carpenter et al, 1994). Light activation of hypericin for 15–30 min
inactivates infectious titers (5–6 log10) of HIV as well as other enveloped
and nonenveloped viruses (Meruelo et al, 1988; Kraus et al, 1990; Tang
et al, 1990; Carpenter and Kraus, 1991; Hudson et al, 1991; Lenard
et al, 1993). In addition, hypericin inhibits the growth of cells derived
from a variety of neoplastic tissues including glioma (Couldwell et al,
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IC50 values of 0.75–3.2 mM. UVA-photoactivated hyper-
icin (0.5–2.0 J per cm2) could also inhibit proliferation
with IC50 values of 0.57–1.8 mM, 0.7–4.6 mM, and 2.0–
3.7 mM for malignant, normal, or Epstein–Barr virus-
transformed cells, respectively. Hypericin, photoactiv-
ated with either UVA or white light, could induce near
complete apoptosis (94%) in malignant cutaneous T cell
lymphoma T cells, whereas lower levels of apoptosis (37–
88%) were induced in normal PBMC. These data indicate
that hypericin inhibits mitogen-induced proliferation of
malignant T cells from patients with cutaneous T cell
lymphoma, PBMC from normal individuals, as well as
Epstein–Barr virus-transformed lymphocytes, and that
inhibition of cell proliferation is dependent on the con-
centration of hypericin used and the dose of light required
to photoactivate the compound. Induction of apoptosis
is, in part, one mechanism by which photoactivated
hypericin inhibits malignant T cell proliferation.
Key words: apoptosis/CTCL/photoactivation. J Invest Derma-
tol 111:327–332, 1998
1994; Zhang et al, 1996), neuroblastoma (Zhang et al, 1995; Diwu,
1995), adenoma (Hamilton et al, 1996), mesothelioma (Koren et al,
1996), melanoma (Thomas and Pardini, 1992; Hadjur et al, 1996),
carcinoma (Andreoni et al, 1994; Migita et al, 1995; VanderWerf et al,
1996), sarcoma (Chung et al, 1994; VanderWerf et al, 1996), and
leukemia (Jarvis et al, 1994). Although the mechanism by which
hypericin exerts its biologic activity is unclear, it has been demonstrated
to inhibit protein kinase activity (Takahashi et al, 1989; Zhang et al,
1995; Agostinis et al, 1996) as well as other enzymes such as monoamine
oxidase (Bladt and Wagner, 1994; Perovic and Muller, 1995) and
mitochondrial succinoxidase, possibly via generation of singlet oxygen
(Thomas et al, 1992). Hypericin does not appear to act by intercalating
into DNA and thus should not possess some of the deleterious side-
effects that have been recently reported with other therapeutic regimens
that utilize intercalating photoactive agents such as psoralen (Stern
et al, 1997).
Cutaneous T cell lymphoma (CTCL) is characterized by the
accumulation of clonal malignant CD41 T cells in the skin and
peripheral blood (Whittaker et al, 1991; Zelickson et al, 1991; Wolff-
Sneedorff et al, 1995). An advanced form of CTCL, the Sezary
syndrome, presents with erythroderma, lymphadenopathy, and the
presence of malignant T cells in the peripheral circulation. The clonal
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nature of these malignant T cells has been well established and it
appears there is not a restricted use of a particular T cell antigen
receptor beta chain (TCR-Vβ) among patients with Sezary syndrome,
although frequently many individuals with Sezary syndrome have an
expansion of malignant T cells expressing a unique T cell clonotype
(Weiss et al, 1989; Lessin et al, 1991; Weinberg et al, 1995; Dummer
et al, 1996). It has been suggested that the particular clone of malignant
T cells might be responsible for the characteristic immune abnormalities
seen in this disease, which include elevated production of Th2 cytokines
(IL-4, IL-5, and IL-10), decreased production of Th1 cytokines (IL-2
and IFN-γ), and decreased cell-mediated immunity (Rook et al, 1993).
The majority of studies on the biologic activities of hypericin have
been performed without specific photoactivation. This study was
designed to determine whether chemically synthesized hypericin is
capable of inhibiting the proliferative responses to mitogens of normal
peripheral blood mononuclear cells (PBMC) or malignant T cells
derived from CTCL patients. In addition, we examined whether
hypericin could inhibit the proliferation of an Epstein–Barr virus
(EBV)-transformed lymphocyte cell line. We also sought to obtain
information regarding the concentrations of hypericin necessary to
cause inhibition and to determine the qualitative and quantitative
nature of light exposure necessary to yield optimal biologic activity of
hypericin. Finally, we determined if apoptosis of hypericin-treated cells
could explain the observed anti-proliferative activity in the cell systems
under study.
MATERIALS AND METHODS
Preparation of cell populations PBMC were prepared as previously
described (Rook et al, 1995). Whole blood obtained from normal healthy
donors or patients with Sezary Syndrome was diluted 2-fold with Dulbecco’s
phosphate buffered saline, layered over Ficoll-Hypaque (Pharmacia, Piscataway,
NJ) and centrifuged for 30 min at 5003g. The interface containing the
mononuclear cell fraction was washed with Dulbecco’s phosphate buffered
saline by centrifugation and resuspended in complete medium at the indicated
cell concentration. In certain experiments, malignant clonal T cells were isolated
using TCR clonotypic specific monoclonal antibodies and immunomagnetic
beads. Briefly, monocytes were depleted from PBMC by adherence to gelatin-
coated tissue culture flasks. The nonadherent fraction was incubated with an
anti-TCR Vβ antibody specific for the expanded malignant clone of the
particular patient (Immunotech, Westbrook, ME) for 30 min at 4°C. The cells
were then washed to remove unbound antibody and then combined with
immunomagnetic beads coated with goat anti-mouse Fc specific antibodies
(Perseptive Diagnostics, MA) at a bead:cell ratio of 25:1. Positively selected
malignant, clonotypic T cells were recovered in a magnetic field and the
selection process repeated on the cells not binding to the beads in this first
round of separation. The TCR Vβ-positively selected cells were pooled and
were determined to be greater than 97% pure by flow cytometric analysis. The
remaining T cells, comprising the unselected clonotypes, were utilized as a
control for the malignant cells in appropriate experiments.
Reagents Chemically synthesized hypericin was supplied by VIMRX
Pharmaceuticals (Wilmington, DE). A stock solution was prepared by dissolving
40 mg Hypericin in 40 ml 2% benzyl alcohol (vehicle) to yield a 2 mM solution
and kept in the dark at 4°C. Eight-methoxypsoralen (8-MOP) was purchased
from Sigma (St. Louis, MO) and a stock solution of 462.5 µM was prepared
by dissolving 100 µg 8-MOP in 1 ml 2% benzyl alcohol and keeping in the
dark at 4°C.
Cell culture and photoactivation Purified cells from normal donors or
patients were diluted to a concentration of 2 3 106 cells per ml with complete
medium and 100 µl were aliquoted into each well of a 96 well microtiter plate.
Medium, vehicle, hypericin, or 8-MOP were 5-fold serially diluted into their
respective set of wells in a darkened tissue culture room (subdued light). One
plate that was to receive no exposure to photoactivating wavelengths of light
was placed immediately in a 37°C incubator. The remaining plates were exposed
to white light from four fluorescent F15T8CW 15 W bulbs 9 cm above the
tissue culture plates. Photoactivation with fluorescent illumination lasted for
between 10 and 30 min and delivered the equivalent of 1.1–3.3 J per cm2.
Alternatively, photoactivation was performed with UVA illumination (320–
400 nm) on a light box utilizing eight UVA-AR bulbs. Photoactivation with
UVA light lasted between 0.5 and 4 min and delivered the equivalent of 0.5–
2.0 J per cm2. The plates were then incubated at 37°C for 24 h or 72 h
depending on the assay to be performed. To quantitate the light delivered to
the medium containing well of a tissue culture plate an IL-700 A research
radiometer (International Light, Newburyport, MA) was used.
Proliferation assay Proliferation was measured by quantitating the incorpora-
tion of tritiated thymidine ([3H]TdR) into newly synthesized DNA. Briefly,
control or treated cells were cultured at 2 3 106 cells per ml in the presence
of ConA (10 µg per ml) for 72 h at 37°C in a humidified, 5% CO2 incubator
in complete medium. During the final 18 h of culture, 0.5 uCi of [3H]TdR
was added to each well. The cells were harvested onto glass fiber filters using
a Skatron Cell Harvester. Incorporated cpm was then quantitated on a
scintillation counter and plotted as shown in the figures.
Apoptosis assay Apoptosis was assessed using a modification of the terminal
dUTP nick end labeling (TUNEL) method previously described by Sgonc et al
(1994), as supplied in kit form by Boehringer (Indianapolis, IN). Apoptotic cell
death is characterized by the internucleosomal cleavage of DNA into fragments
of µ180 bp. The TUNEL assay allows for the incorporation of flourescein
labeled-dUTP (FITC-dUTP) into the free ends of these apoptotic DNA
fragments. In addition, by using a flow cytometric analysis, apoptotic cells can
be distinguished from necrotic cells because apoptotic cells will retain their cell
membrane integrity (and relative size) that is reflected in little or no change in
their forward light scattering properties. Cells that do not change in size and
incorporate FITC-dUTP label can reliably be identified as apoptotic. Briefly,
cells cultured as described above were fixed in 4% paraformaldehyde for 30 min
at 25°C, and permeabilized in 0.1% Triton containing 0.1% sodium citrate for
2 min on ice. Terminal deoxynucleotide transferase (vial 1) and nucleotide
mixture (vial 2) were then added to the cells and the mixture was incubated
for 60 min at 37°C. Then, using a FACScan flow cytometer (Becton Dickinson),
the percentage of cells (of the 10,000 total acquired) undergoing apoptosis was
determined as:
Number of cells incorporating FITC-dUTP into fragmented DNA
3100
Total number of cells
RESULTS
Photoactivation of hypericin with white light potentiates its
anti-proliferative effect To examine the role of photoactivated
hypericin on proliferative responses of lymphocytes to mitogenic
stimulation, normal, neoplastic, or EBV-transformed lymphocytes were
cultured with or without increasing amounts of hypericin. These
cultures were kept in subdued light to minimize any photoactivation
of hypericin or were illuminated with white light for increasing
amounts of time. When normal lymphocytes were kept in subdued
light (Fig 1A), hypericin induced a small but significant inhibition of
proliferation of these cells. We observed that benzyl alcohol vehicle
toxicities at higher concentrations began interfering with the hypericin
mediated inhibition of lymphocyte proliferation, making an exact
calculation of an IC50 for nonphotoactivated hypericin impossible. An
approximation of the minimum calculated IC50 for nonphotoactivated
hypericin would be of the order of 22 µM. When similar cultures
were illuminated with white light for 10 min (1.1 J per cm2), the IC50
for hypericin was 0.8 µM (µ27-fold increase) (Fig 1B). Complete
inhibition of proliferation of normal lymphocytes was achieved by
µ3.2 µM hypericin and 1.1 J light per cm2. Increasing the light
exposure (duration of photoactivation) with white light to 20 min
(2.2 J per cm2) (Fig 1C) decreased the IC50 for hypericin to 0.1 µM
(µ220-fold increase), and complete inhibition of cell proliferation at
this light dose was observed at a concentration of 0.64 µM hypericin.
The increased level of inhibition observed when hypericin-treated
lymphocytes were illuminated for 20 min, compared with illumination
for 10 min, suggests that there is an optimal activation time needed
for maximal efficacy of hypericin. Illumination of hypericin-treated
lymphocytes for 30 min (IC50 5 0.17 µM, data not shown) did not
significantly increase the inhibition of cell proliferation, which suggests
that the optimal anti-proliferative activity can be elicited when hypericin
is photoactivated for between 10 and 20 min (1.1–2.2 J per cm2).
Hypericin photoactivation studies utilizing peripheral blood cells
from a patient having leukemic CTCL (Sezary syndrome) are depicted
in Fig 2. Previous characterization of this patient’s peripheral blood
lymphocytes by flow cytometry indicated that 99% of these cells were
CD41/CD8–/Vβ221, suggesting that the vast majority had an abnormal
phenotype that was contained within a single clonal population. In
cultures of these lymphocytes, which were illuminated for 20 min, the
IC50 for hypericin was 0.3 µM, and complete inhibition of cell
proliferation was observed at a concentration of 3.2 µM hypericin
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Figure 1. Inhibition of normal PBMC proliferation by photoactivating
hypericin with white light. PBMC from normal individuals were incubated
with ConA (10 µg per ml) with or without 5-fold serial dilutions of hypericin
and at the indicated concentrations. Cultures were then left (A) unexposed, (B)
exposed to 10 min (1.1 J per cm2) white light, or (C) exposed to 20 min (2.2 J
per cm2) white light prior to culturing for a further 72 h. Proliferation as
determined by the amount of newly synthesized DNA present was quantitated
during the final 18 h of culture by measuring incorporation of [3H]TdR. Data
are represented as the mean 6 SD of triplicate points from the same individual.
(Fig 2B). In cultures of Sezary lymphocytes that were kept in subdued
light, an approximation of the minimum IC50 for nonphotoactivated
hypericin would be 34 µM (Fig 2A). These data indicate that hypericin
inhibits mitogen-induced proliferation of normal and malignant
human PBMC.
We also examined the ability of photoactivated hypericin to inhibit
the proliferation of cells transformed with EBV because this represents
a model of a B cell lymphoproliferative disorder (Fig 3B). In cultures
of EBV-transformed lymphocytes illuminated for 10 min with white
light, the IC50 for hypericin was 3.2 µM (11.3-fold over nonphotoactiv-
ated). In cultures of transformed lymphocytes illuminated for 30 min,
the IC50 for hypericin was 0.75 µM (48-fold over nonphotoactivated),
and complete inhibition of cell proliferation was observed at a concen-
tration of 3.2 µM hypericin. In contrast, in cultures of transformed
lymphocytes that were not illuminated, the approximate minimum
IC50 for nonphotoactivated hypericin would be 36 µM. In contrast
to the results obtained using normal lymphocytes, illumination of
transformed lymphocytes for a period of 30 min resulted in inhibition
of proliferation greater than that observed from photoactivation for
periods of 10 or 20 min (Fig 3B). These results indicate that the
optimal period of photoactivation of hypericin may be expected to
vary, depending upon the characteristics of the lymphocytes or cells to
be affected.
Photoactivation of hypericin with ultraviolet light also potenti-
ates its anti-proliferative effect Because hypericin exhibits absorb-
Figure 2. Inhibition of malignant T cell proliferation by photoactivating
hypericin with white light. Malignant T cells from patients with CTCL
were incubated with ConA (10 µg per ml) with or without 5-fold serial
dilutions of hypericin at the indicated concentrations. Cultures were then left
(A) unexposed or (B) exposed to 20 min white light prior to culturing for a
further 72 h. Proliferation as determined by the amount of newly synthesized
DNA present was quantitated during the final 18 h of culture by measuring
incorporation of [3H]TdR. Data are represented as the mean 6 SD of triplicate
points from the same individual.
ence peaks in the UVA region (327 nm) of the electromagnetic
spectrum as well as the visible region (563 and 603 nm) (Fig 4), we
wanted to determine the ability of hypericin to inhibit proliferation of
lymphocytes upon photoactivation with UVA light. In addition, we
compared the anti-proliferative effects of 8-MOP, another UVA
photoactivatable compound, to those of hypericin.
The ability of 8-MOP to inhibit proliferation of EBV-transformed
lymphocytes was not evident and thus was not enhanced upon
illumination using white light (Fig 3A). In contrast, as indicated by
the data depicted in Fig 3(B), the ability of hypericin to inhibit
proliferation of EBV-transformed lymphocytes was enhanced signifi-
cantly upon photoactivation with white light. In the absence of white
light illumination, the approximate minimum IC50 for hypericin was
calculated to be 36 µM; following 30 min of white light illumination,
the IC50 for hypericin was 0.75 µM.
The ability of both hypericin and 8-MOP to inhibit proliferation
of EBV-transformed lymphocytes was enhanced significantly upon
illumination using UVA light. In the absence of UVA illumination,
the approximate minimum IC50 for 8-MOP could not be calculated
and the approximate minimum IC50 for hypericin (Fig 3D) was
calculated to be 36 µM; following 2 J UVA illumination per cm2, the
IC50 for 8-MOP (Fig 3C) was 0.7 µM and the IC50 for hypericin
was 2.0 µM. Furthermore, the ability of hypericin to inhibit cell
proliferation was essentially the same whether 2 or 1 J UVA illumination
per cm2 was applied. In contrast, the ability of 8-MOP to inhibit cell
proliferation roughly doubled when 2 J UVA illumination per cm2
was applied, relative to when 1 J UVA illumination per cm2 was
applied (at the 0.7 µM concentration). These results indicate that less
UVA illumination is required to elicit the maximal anti-proliferative
effect of hypericin than is necessary to elicit the maximal anti-
proliferative activity of 8-MOP.
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Figure 3. Effect of photoactivation with visible or UVA light on
hypericin or 8-MOP inhibition of EBV-transformed B lymphocyte
proliferation. EBV-transformed lymphocytes were incubated in complete
medium with or without 5-fold serial dilutions of hypericin (B, D) or 8-MOP
(A, C) at the indicated concentrations. (A, B) Cultures were then left unexposed
(l) or exposed to 10 min [1.1 J per cm2] (n), 20 min [2.2 J per cm2] (s), or
30 min [3.3 J per cm2] (t) of white light prior to culturing for a further 72 h.
(C, D) Cultures were then left unexposed (l) or exposed to 0.5 J per cm2 (n),
1.0 J per cm2 (s), or 2.0 J per cm2 (t) of UVA light prior to culturing for a
further 72 h. Proliferation as determined by the amount of newly synthesized
DNA present was quantitated during the final 18 h of culture by measuring
incorporation of [3H]TdR. Data are represented as the mean 6 SD of triplicate
points from the same individual.
Figure 4. Absorbance spectrum of 20 mM hypericin in phosphate
buffered saline. Hypericin stock solution was dissolved in phosphate buffered
saline to a final concentration of 20 µM and a spectrum was acquired using a
Beckman DU-640 spectrophotometer.
Induction of apoptosis of lymphocytes using photoactivated
hvpericin In an effort to investigate the mechanisms of the anti-
proliferative effects of hypericin, we determined whether hypericin
treated lymphocytes were induced to undergo apoptosis. The ability
Figure 5. Induction of apoptosis in normal PBMC by photoactivated
hypericin or 8-MOP. Medium (row 1), 10 µM hypericin (row 2), or 0.462 µM
(100 ng per ml) 8-MOP (row 3) were added to cultures of PBMC from normal
individuals. These cultures were then left unexposed (column 1) or exposed to
20 min white light (column 2) or 2 J UVA light per cm2 (column 3). Cultures
were then placed at 37°C for 24 h. Percentage apoptosis was determined using
a TUNEL assay as described in Materials and Methods.
Figure 6. Induction of apoptosis in malignant T cells by photoactivated
hypericin or 8-MOP. Medium (row 1), 10 µM hypericin (row 2), or 0.462 µM
(100 ng per ml) 8-MOP (row 3) were added to cultures of malignant T cells
from individuals with CTCL. These cultures were then left unexposed (column
1) or exposed to 20 min white light (column 2) or 2 J UVA light per cm2
(column 3). Cultures were then placed at 37°C for 24 h. Percentage apoptosis
was determined using a TUNEL assay as described in Materials and Methods.
of photoactivated hypericin to induce apoptosis in PBMC from a
representative normal individual (Fig 5) or neoplastic lymphocytes
from a patient with CTCL (Fig 6) was compared with the ability of
photoactivated 8-MOP to induce apoptosis in these cells. Hypericin-
treated, 8-MOP-treated, or untreated normal lymphocytes or malignant
T cells were photoactivated using white light for 20 min or 2 J UVA
light per cm2, or were not photoactivated. After 18 h, apoptotic cells
(cells above the diagonal line) were distinguished from nonapoptotic
cells based on increased dUTP-FITC incorporation using flow cytome-
try. Normal or neoplastic cells incubated with either hypericin or
8-MOP did not induce a significant increase in apoptosis in the absence
of photoactivation (Figs 5, 6, column 1). Hypericin photoactivated
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Table I. Induction of apoptosis in Vb81 and Vb8– CTCL T
cells by photoactivated hypericin or 8-MOPa
Photoactivation source
2.2 J per cm2 2 J per cm2
None visible UVA
Vβ81 Vβ8– Vβ81 Vβ8– Vβ81 Vβ8–
Vehicle 18 7 18 20 35 ND
Hypericin, 10 µM 21 8 96 90 96 80
8-MOP, 10 µM 16 5 16 18 85 83
aThe malignant clonotypic T cells (TCR Vβ81 cells) were positively selected from the
nonmalignant T cells (TCR Vβ8– cells) in an individual with a previously identified clonal
T cell population as described in Materials and Methods. The two populations were incubated
with vehicle or either hypericin (10 µM) or 8-MOP (10 µM) in the dark (no exposure)
or followed by photoactivation with either visible or UVA light. Apoptosis was measured
24 h later using the TUNEL procedure. Values represent the percentage of Vβ81 or Vβ8–
cells undergoing apoptosis. ND, not done.
with white light induced apoptosis in nearly all normal and malignant
cells (87.9 and 94.3%, respectively, Figs 5, 6). The completeness of
apoptosis induction can also be seen by a disappearance of the cells
below the diagonal. This occurs only in cultures treated with hypericin
and subsequent photoactivation. White light-activated 8-MOP induced
apoptosis in a minimal number of each cell type (15.3% and 12.2%,
respectively). Malignant cells treated with hypericin or 8-MOP photo-
activated with 2 J UVA per cm2 (Fig 6, column 3) demonstrated
induction of apoptosis levels near or comparable with hypericin
photoactivated with white light. Normal cells treated with hypericin
or 8-MOP photoactivated with 2 J UVA per cm2 (Fig 5, column 3)
demonstrated significant induction of apoptosis but at levels lower than
that of hypericin photoactivated with white light.
To investigate whether hypericin was inducing apoptosis preferen-
tially in malignant versus nonmalignant T cells present in the blood of
individuals with CTCL, we positively selected the malignant clonotypic
T cells (TCR Vβ81 cells) from the nonmalignant T cells (TCR Vβ8–
cells) from an individual with a previously identified clonal T cell
population. These two populations were incubated with vehicle or
either hypericin (10 µM) or 8-MOP (10 µM) in the dark (no exposure)
or followed by photoactivation with either visible or UVA light. As
can be seen in Table I, in cultures kept in the dark there is some
increased level of apoptosis in Vb81 cells when compared with Vβ8–
cells (16–21% vs 5–8%). In cultures photoactivated with white light,
hypericin does not appear to selectively induce apoptosis in the
malignant versus nonmalignant T cells; however, in the presence of
UVA, hypericin induces greater levels of apoptosis in Vβ81 cells than
in Vβ8– cells (96% vs 80%), whereas 8-MOP does not appear to have
any selective effect. In addition, these data also suggest that hypericin
photoactivated with either visible or UVA light may be a more potent
inducer of malignant T cell apoptosis than 8-MOP.
DISCUSSION
Hypericin is a photodynamic agent that has documented activity against
a wide variety of neoplastic cells (Thomas and Pardini, 1992; Couldwell
et al, 1994; Andreoni et al, 1994; Chung et al, 1994; Jarvis et al, 1994;
Zhang et al, 1995, 1996; Diwu, 1995; Migita et al, 1995; Hamilton
et al, 1996; Koren et al, 1996; Hadjur et al, 1996; VanderWerf et al,
1996). In the presence of light, hypericin has been described to excite
oxygen to its singlet state (Duran and Song, 1986; Thomas et al, 1992;
Diwu and Lown, 1993). In addition, hypericin has been shown to be
involved in the generation of superoxide anion radicals (Diwu and
Lown, 1993). Hypericin can be optimally photoactivated by light of
about 570–650 nm wavelength, i.e., in the yellow region (Meruelo
et al, 1988; Lavie et al, 1989; Thomas et al, 1992), but can also be
activated by UVA light (Figs 3, 5, 6) to potentiate its biologic activity.
Hypericin binds to phospholipids such as phosphatidylcholine of cell
membranes, and it binds to retroviral particles, probably by associating
with the membrane-derived lipid envelope (Lavie et al, 1995).
Recent data also suggest that hypericin is an inhibitor of protein
tyrosine and serine/threonine kinase activity (deWitte et al, 1993;
Agostinis et al, 1996). Specifically, hypericin has been demonstrated to
inhibit the action of protein kinase C (Takahashi et al, 1989; Zhang
et al, 1995; Utsumi et al, 1995; Hamilton et al, 1996) through direct
interaction with the regulatory domain of the enzyme, although there
is at least one report of it having no inhibitory effect on PKC activity
(Jarvis et al, 1994). Hypericin was not photoactivated, however, which
may account for its lack of PKC inhibitory activity in that study. Direct
interaction of hypericin with PKC might be one potential mechanism
by which hypericin can induce apoptosis of lymphoid cells. Several
compounds (i.e., H7, staurosporine) that can inhibit PKC activity have
been shown to cause various neoplastic cell types to undergo apoptosis
(Jarvis et al, 1994; Zhang et al, 1995). It is also possible that photoactiv-
ated hypericin may be acting indirectly, through the generation of
singlet oxygen, to inhibit proliferation and induce apoptosis. Whether
singlet oxygen generation resulting from photoactivation of hypericin
is causally related to inhibition of PKC and induction of apoptosis is
not known at this time. Nevertheless, at this time it is not clear what
role singlet oxygen may have on protein kinase activity.
A possible mechanism by which the leukemic T cells in CTCL
accumulate in the skin and blood may be due to deficient or absent
apoptosis, because they do not exhibit strong spontaneous proliferation
as measured by [3H]TdR incorporation. Implicit in the results of this
study are that the topical or systemic administration of hypericin,
followed by photoactivation, could lead to a beneficial therapeutic
effect in CTCL by eliminating malignant T cells through the induction
of apoptosis. Moreover, other inflammatory skin diseases typified by
lymphocytic infiltrates, including psoriasis and lichen planus, might
also be treated with topical hypericin.
Hypericin has several attributes that make it particularly attractive
for investigating its clinical use in skin disorders with potential
advantages over phototherapy with psoralen plus UVA. Hypericin has
been shown to possess little toxicity when administered systemically
(Meruelo et al, 1988), and is maximally activated by white light at
wavelengths produced by the sodium lamp (590 nm), which signifi-
cantly reduces the side-effects associated with UV irradiation. There
have been several recent reports that UVA exposure, particularly in
the course of psoralen plus UVA therapy, may have long-term
detrimental effects including mutagenesis and skin cancer development
(Stern et al, 1997). Whether these detrimental effects occur as a result
of the primary irradiation or as a result of secondary immunosuppression
is still under investigation (Wang et al, 1997; Van de Kerkhof and
de Rooij, 1997). Hence, the use of hypericin potentially permits
minimization of exposure to UV illumination and therefore minimiza-
tion of the undesirable effects of UVA illumination. In addition,
hypericin has a relatively long half-life (20–24 h) that allows for
repeated light activation with single doses (Liebes et al, 1991; Staffeldt
et al, 1994). Hypericin has been demonstrated to be present in skin
after systemic administration and it has been shown to be about 20%
bioavailable after oral administration (Kerb et al, 1996). Furthermore,
the mechanism of photoreactions (singlet oxygen production and
apoptosis) are the same as other phototherapeutic agents that have been
shown to be beneficial in the treatment of inflammatory skin diseases.
A phase I safety study with normal volunteers using photoactivated
hypericin has been completed (data on file, VimRx Pharmaceuticals,
Wilmington, DE) and a clinical trial using hypericin as photodynamic
therapy to treat inflammatory skin diseases has been initiated. The
potential clinical relevance of this interesting agent will soon be
understood.
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